PIONIER: a visitor instrument for the VLTI

PIONIER is a 4-telescope visitor instrument for the VLTI, planned to see its first fringes in 2010. It combines four ATs or four UTs using a pairwise ABCD integrated optics combiner that can also be used in scanning mode. It provides low spectral resolution in H and K band. PIONIER is designed for imaging with a specific emphasis on fast fringe recording to allow closure-phases and visibilities to be precisely measured. In this work we provide the detailed description of the instrument and present its updated status.Comment: Proceedings of SPIE conference Optical and Infrared Interferometry II (Conference 7734) San Diego 201

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

BACKGROUND: The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA, the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year. METHODS: In this 52-week, multicentre, randomised, double-blind, parallel-group study, male and female patients (aged at least 40 years) with symptomatic primary OA of the hip, knee, hand or spine were randomised (1:2:1) to lumiracoxib 100 mg o.d. (n = 755), lumiracoxib 100 mg b.i.d. (n = 1,519) or celecoxib 200 mg o.d. (n = 758). The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d. with respect to the 1-year retention on treatment rate. Secondary outcome variables included OA pain in the target joint, patient's and physician's global assessments of disease activity, Short Arthritis assessment Scale (SAS) total score, rescue medication use, and safety and tolerability. RESULTS: Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d., lumiracoxib 100 mg b.i.d. and celecoxib 200 mg o.d. groups (46.9% vs 47.5% vs 45.3%, respectively). It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d. Similarly, Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups. All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated. CONCLUSION: Long-term treatment with lumiracoxib 100 mg o.d., the recommended dose for OA, was as effective and well tolerated as celecoxib 200 mg o.d. in patients with OA. TRIAL REGISTRATION: clinicaltrials.gov NCT00145301

What’s retinoic acid got to do with it? Retinoic acid regulation of the neural crest in craniofacial and ocular development

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151310/1/dvg23308.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/151310/2/dvg23308_am.pd

A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.

Contains fulltext : 70565.pdf (publisher's version ) (Closed access)The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP changes; these might be of clinical relevance

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Contains fulltext : 57937.pdf (publisher's version ) (Closed access)BACKGROUND: The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen. METHODS: 18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) in two substudies of identical design. Randomisation was stratified for low-dose aspirin use and age. The primary cardiovascular endpoint was the Antiplatelet Trialists' Collaboration endpoint of non-fatal and silent myocardial infarction, stroke, or cardiovascular death. Analysis was by intention to treat. FINDINGS: 81 (0.44%) patients did not start treatment and 7120 (39%) did not complete the study. At 1-year follow-up, incidence of the primary endpoint was low, both with lumiracoxib (59 events [0.65%]) and the non-steroidal anti-inflammatory drugs (50 events [0.55%]; hazard ratio 1.14 [95% CI 0.78-1.66], p=0.5074). Incidence of myocardial infarction (clinical and silent) in the overall population in the individual substudies was 0.38% with lumiracoxib (18 events) versus 0.21% with naproxen (ten) and 0.11% with lumiracoxib (five) versus 0.16% with ibuprofen (seven). In the naproxen substudy, rates of myocardial infarction (clinical and silent) did not differ significantly compared with lumiracoxib in the population not taking low-dose aspirin (hazard ratio 2.37 [95% CI 0.74-7.55], p=0.1454), overall (1.77 [0.82-3.84], p=0.1471), and in patients taking aspirin (1.36 [0.47-3.93], p=0.5658). In the ibuprofen substudy, these rates did not differ between lumiracoxib and ibuprofen in the population not taking low-dose aspirin (0.75 [0.20-2.79], p=0.6669), overall (0.66 [0.21-2.09], p=0.4833), and in patients taking aspirin (0.47 [0.04-5.14], p=0.5328). INTERPRETATION: The primary endpoint, including incidence of myocardial infarction, did not differ between lumiracoxib and either ibuprofen or naproxen, irrespective of aspirin use. This finding suggests that lumiracoxib is an appropriate treatment for patients with osteoarthritis, who are often at high cardiovascular risk and taking low-dose aspirin

PIONIER: a 4-telescope visitor instrument at VLTI

Context. PIONIER stands for Precision Integrated-Optics Near-infrared Imaging ExpeRiment. It combines four 1.8m Auxilliary Telescopes or four 8m Unit Telescopes of the Very Large Telescope Interferometer (ESO, Chile) using an integrated optics combiner. The instrument was integrated at IPAG in December 2009 and commissioned at the Paranal Observatory in October 2010. It has provided scientific observations since November 2010. Aims: In this paper, we explain the instrumental concept and describe the standard operational modes and the data reduction strategy. We present the typical performance and discuss how to improve them. Methods: This paper is based on laboratory data obtained during the integrations at IPAG, as well as on-sky data gathered during the commissioning at VLTI. We illustrate the imaging capability of PIONIER on the binaries δ Sco and HIP11231. Results: PIONIER provides six visibilities and three independent closure phases in the H band, either in a broadband mode or with a low spectral dispersion (R = 40), using natural light (i.e. unpolarized). The limiting magnitude is Hmag = 7 in dispersed mode under median atmospheric conditions (seeing 3ms) with the 1.8m Auxiliary Telescopes. We demonstrate a precision of 0.5deg on the closure phases. The precision on the calibrated visibilities ranges from 3% to 15% depending on the atmospheric conditions. Conclusions: PIONIER was installed and successfully tested as a visitor instrument for the VLTI. It permits high angular resolution imaging studies at an unprecedented level of sensitivity. The successful combination of the four 8m Unit Telescopes in March 2011 demonstrates that VLTI is ready for four-telescope operation. Based on observations collected at the European Southern Observatory, Paranal, Chile (commissioning data and 087.C-0709)

PIONIER: a 4-telescope visitor instrument at VLTI

PIONIER stands for Precision Integrated-Optics Near-infrared Imaging ExpeRiment. It combines four 1.8m Auxilliary Telescopes or four 8m Unit Telescopes of the Very Large Telescope Interferometer (ESO, Chile) using an integrated optics combiner. The instrument has been integrated at IPAG starting in December 2009 and commissioned at the Paranal Observatory in October 2010. It provides scientific observations since November 2010. In this paper, we detail the instrumental concept, we describe the standard operational modes and the data reduction strategy. We present the typical performance and discuss how to improve them. This paper is based on laboratory data obtained during the integrations at IPAG, as well as on-sky data gathered during the commissioning at VLTI. We illustrate the imaging capability of PIONIER on the binaries deltaSco and HIP11231. PIONIER provides 6 visibilities and 3 independent closure phases in the H band, either in a broadband mode or with a low spectral dispersion (R=40), using natural light (i.e. unpolarized). The limiting magnitude is Hmag=7 in dispersed mode under median atmospheric conditions (seeing3ms) with the 1.8m Auxiliary Telescopes. We demonstrate a precision of 0.5deg on the closure phases. The precision on the calibrated visibilities ranges from 3 to 15% depending on the atmospheric conditions. PIONIER has been installed and successfully tested as a visitor instrument for the VLTI. It permits high angular resolution imaging studies at an unprecedented level of sensitivity. The successful combination of the four 8m Unit Telescopes in March 2011 demonstrates that VLTI is ready for 4-telescope operation